Observational analysis found liraglutide improved insulin secretion in prediabetic mice, suggesting it may inhibit inflammation and regulate gut microbiota.
Key Points
Liraglutide treatment improved insulin secretion and reduced inflammation in prediabetic mice, leading to better glycemic control.
Prediabetic mice exhibited increased inflammation, glucose levels, and weight before liraglutide treatment over 12 weeks.
Liquid chromatography-mass spectrometry assessed gut microbiota changes post liraglutide intervention, focusing on Desulfovibrio.
These findings support the potential of liraglutide to delay or prevent progression from prediabetes to diabetes.